U.S. Markets closed

Arena Pharmaceuticals, Inc. (ARNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
80.50-0.06 (-0.07%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close80.56
Open80.00
Bid79.90 x 1000
Ask81.75 x 800
Day's Range79.00 - 81.81
52 Week Range32.95 - 90.19
Volume471,294
Avg. Volume712,484
Market Cap4.682B
Beta (5Y Monthly)0.83
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Is ARNA A Good Stock To Buy Now?
    Insider Monkey

    Is ARNA A Good Stock To Buy Now?

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Just Reported And Analysts Have Been Cutting Their Estimates
    Simply Wall St.

    Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Just Reported And Analysts Have Been Cutting Their Estimates

    Shareholders in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) had a terrible week, as shares crashed 23% to US$67.10 in...

  • Here's Why Arena Pharmaceuticals Stock Is Plummeting Today
    Motley Fool

    Here's Why Arena Pharmaceuticals Stock Is Plummeting Today

    Shares of Arena Pharmaceuticals (NASDAQ: ARNA) are plummeting today, down by 22% as of 1:35 p.m. EST, after the biotech released data from a mid-stage study of etrasimod in patients with atopic dermatitis, commonly called eczema. The good news is that there are some hints that etrasimod might be helping patients with eczema. Using that measurement, there wasn't a statistical difference between either of the two dose levels of etrasimod compared to a placebo after 12 weeks of treatment.